Stockscreener 앱 받기
0.16%
전일 마감가:
$297.40
열려 있는:
$297.72
하루 거래량:
2.52M
Relative Volume:
1.14
시가총액:
$160.37B
수익:
$34.76B
순이익/손실:
$6.62B
주가수익비율:
24.37
EPS:
12.223
순현금흐름:
$10.61B
1주 성능:
+9.13%
1개월 성능:
+4.95%
6개월 성능:
-3.86%
1년 성능:
-6.17%
1일 변동 폭
$295.63
$301.54
1주일 범위
$270.67
$301.66
52주 변동 폭
$253.30
$335.88
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
AMGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
297.89 | 160.11B | 34.76B | 6.62B | 10.61B | 12.22 |
|
LLY
Lilly Eli Co
|
839.87 | 734.96B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.64 | 447.90B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
233.91 | 417.90B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
132.39 | 253.54B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
89.19 | 223.58B | 63.43B | 16.42B | 14.72B | 6.4861 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Should I buy Amgen Inc. (AMG0) stock before earnings seasonPortfolio Update Report & Growth Oriented Trade Recommendations - newser.com
Amgen Inc. $AMGN Shares Acquired by O Keefe Stevens Advisory Inc. - MarketBeat
Amgen Inc. $AMGN Shares Sold by Boston Common Asset Management LLC - MarketBeat
Amgen Inc. $AMGN Stock Position Lifted by Talbot Financial LLC - MarketBeat
Ameriflex Group Inc. Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Ascent Group LLC - MarketBeat
Ameritas Advisory Services LLC Has $1.23 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
How Amgen Inc. (AMGN) Affects Rotational Strategy Timing - news.stocktradersdaily.com
(AMGN) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
(AMGN) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Amgen Inc (AMGN) Ramps Up Manufacturing Capacity in US, Amidst Hefty Tariffs - MSN
Trading the Move, Not the Narrative: (AMGN) Edition - news.stocktradersdaily.com
AMF Tjanstepension AB Grows Stake in Amgen Inc. $AMGN - MarketBeat
4 Reasons to Buy Amgen Stock Right Now - Nasdaq
QRG Capital Management Inc. Increases Position in Amgen Inc. $AMGN - MarketBeat
Corundum Group Inc. Grows Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Lifted by Precedent Wealth Partners LLC - MarketBeat
Franklin Street Advisors Inc. NC Sells 21,044 Shares of Amgen Inc. $AMGN - MarketBeat
The Technical Signals Behind (AMGN) That Institutions Follow - news.stocktradersdaily.com
Sen. Sheldon Whitehouse Sells Amgen Inc. (NASDAQ:AMGN) Stock - MarketBeat
Amgen (NASDAQ:AMGN) Upgraded to Buy at Wall Street Zen - MarketBeat
(AMGN) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
(AMGN) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Colorado Adopts First State Payment Cap for Amgen’s Enbrel (1) - Bloomberg Law News
Cramer's Stop Trading: Amgen - MSN
How (AMGN) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Long-term benefit of Amgen’s Repatha in reducing MACE shown in Phase III trial - Yahoo Finance
Greenwood Capital Associates LLC Sells 5,673 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Mattern Capital Management LLC - MarketBeat
Hilltop National Bank Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Amgen stock maintains Outperform rating at Oppenheimer after positive Repatha trial - Investing.com
Amgen Inc. $AMGN Stock Position Lifted by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Amgen (AMGN) Is Up 9.7% After Repatha Trial Success and Puerto Rico Expansion Announcement – What's Changed - simplywall.st
Amgen Inc. $AMGN Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Is Amgen Inc. (AMG0) stock a buy for dividend portfoliosJuly 2025 Chart Watch & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Amgen Inc. (AMG0) stock extend growth story2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
Will Amgen Inc. price bounce be sustainable2025 Biggest Moves & Smart Money Movement Tracker - newser.com
Why global investors buy Amgen Inc. (AMG0) stockPortfolio Update Report & Weekly Breakout Opportunity Watchlist - newser.com
What data driven models say about Amgen Inc.’s futureJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Precision Trading with Amgen Inc. (AMGN) Risk Zones - news.stocktradersdaily.com
Short interest data insights for Amgen Inc.Weekly Profit Recap & AI Driven Price Forecasts - newser.com
Primary-Prevention Data Should Boost Uptake Of Amgen’s Repatha - insights.citeline.com
Responsive Playbooks and the AMGN Inflection - news.stocktradersdaily.com
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap - Benzinga
Cartography Bio maps out cancer drug plan with $67 million from Pfizer, Amgen venture units and more - The Business Journals
Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings - FinancialContent
Amgen (AMGN): Examining Valuation After Recent 6% Share Price Rise - Yahoo Finance
Amgen claims ‘landmark’ study result that could widen heart drug’s use - BioPharma Dive
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term - sharewise.com
(AMGN) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Amgen (AMGN) Hits Key Milestones with Repatha in Cardiovascular Trial - GuruFocus
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.07%
0.36%
자본화:
|
볼륨(24시간):